Intelligence · Patents
Patents expiring in 2033
Annual patent cliff calendar for 2033 — US pharmaceutical patents by expiration date.
- Patents
- 1,330
Quick answer
1,330 indexed pharmaceutical patents have expiration dates in 2033. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 8426379
POT1 alternative splicing variants
granted -
US 8426365
Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure
granted -
US 8425933
Abuse-resistant oral dosage forms and method of use thereof
granted -
US 8425930
Prebiotic oligosaccharides
granted -
US 8426188
Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
granted -
US 8426179
Synthetic peptide and peptide conjugates and related tissue coupling methods via transglutaminase enzyme
granted -
US 8425653
Plasmon mediated photoinduced synthesis of silver triangular bipyramids
granted -
US 8425492
In vivo device, system and usage thereof
granted -
US 8425459
Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
granted -
US 8425447
Selective cytopheresis devices and related methods thereof
granted -
CA 2851057
UTILISATION COMBINEE D'UN GLYCOSAMINOGLYCANE SULFATE ET D'UNE HYALURONIDASE POUR AMELIORER LA BIODISPONIBILITE DU FACTEUR VIII
granted -
CA 2852397
UTILISATION DE GLYCOSAMINOGLYCANES SULFATES POUR AMELIORER LA BIODISPONIBILITE DU FACTEUR VIII
granted -
US 8431532
FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same
granted -
US 8431570
Methods of utilizing arylpiperazine derivatives
granted -
US 8430832
Selective cytopheresis devices and related methods thereof
granted -
US 8431176
Liquid chromatographic fraction of enzymatically polymerized flavonoid as an antioxidant
granted -
US 8431124
Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP)
granted -
US 8431626
Disulfide monomers comprising ethylenically unsaturated norbornyl groups suitable for dental compositions
granted -
US 8431594
Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors
granted -
US 8431690
T cell receptors and related materials and methods of use
granted -
US 8431605
Modulators of ATP-binding cassette transporters
granted -
US 8431615
Dose forms
granted -
US 8431556
C-21-keto lupane derivatives preparation and use thereof
granted -
US 8431566
Cyclopamine lactam analogs and methods of use thereof
granted -
US 8431561
Methods and compositions for treatment of excess nitric oxide or cyanide toxicity
granted -
US 8431558
Compositions and methods for modification of biomolecules
granted -
US 8431543
Chitosan based polymer conjugate and a method for producing the same
granted -
US 8431380
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
granted -
US 8431154
Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
granted -
US 8431116
Norovirus vaccine formulations
granted -
US 8431134
Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen
granted -
AU 2012205809
Phenethylsulfone isoindoline derivatives as inhibitors of PDE 4 and/or cytokines
granted -
US 8436078
Dental composition and composite resin
granted -
US 8435993
Methods of inhibiting metastasis from cancer
granted -
US 8435504
Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid
granted -
US 8435507
Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
granted -
US 8436224
Methods for testing for caloric restriction (CR) mimetics
granted -
US 8436200
Process for making (R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-flouro-4- iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione and intermediates thereof
granted -
US 8436014
Solid forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluorormethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihyroquinoline-3-carboxamide
granted -
US 8436043
Heterocyclic compound
granted -
US 8435995
Pyridazinone compounds
granted -
US 8436154
Crystallizing method of erythromycin
granted -
US 8435960
Devices for improved wound management
granted -
US 8435979
Use of imipramine blue and analogs thereof in treating cancers
granted -
US 8435533
Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of Chlamydia
granted -
US 8435941
Mini-hepcidin peptides and methods of using thereof
granted -
US 8435575
Use of gingerols for cancer patients suffering from nausea and emesis induced by chemotherapy
granted -
US 8435570
Nitrite formulations and their use as nitric oxide prodrugs
granted
Frequently asked questions
How many pharma patents expire in 2033?
1,330 published patents in our USPTO index have expiration dates falling in calendar year 2033.